Abstract

Poster Presentations

Day 3, June 24（Tue.）　

Room P (Maesato East, Foyer, Ocean Wing)

3P-AM-23
PDF

Comparative Analysis of Effector Function-Related Anti-RBD IgG Glycosylation Profiles in End-Stage Renal Disease Patients After COVID-19 Vaccination

(¹Taipei Medical University, Taiwan, ²Wan Fang Hospital-Nephrology, Taiwan, ³Wan Fang Hospital-Pulmonary, Taiwan)
^oKai-Tang Yu¹, Chung-Yi Cheng², Chih-Hsin Lee³, I-Lin Tsai¹

End-Stage Renal Disease (ESRD) patients have an elevated risk of severe COVID-19 and reduced response to vaccination due to their immunocompromised status. Vaccines induce antibodies and affect the immune response through antibody glycosylation and associated effector functions. While previous study has shown alterations in glycosylation profiles in dialysis patients following their fourth COVID-19 vaccination, there is limited understanding of individual variability, particularly vaccine non-responders. Furthermore, although COVID-19 may no longer be as urgent, identifying early predictors of vaccine immune response is crucial to developing personalized prevention strategies for future variants or outbreaks. Therefore, this study aims to investigate site-specific Fc glycosylation of anti-RBD IgG in first-dose COVID-19 vaccine responders and non-responders among ESRD patients.

Plasma samples were collected from ESRD patients who had received COVID-19 vaccinations, classified into responder and non-responder groups based on their RBD-specific antibody concentrations. The results showed significant differences in IgG1 fucosylation, bisection, monogalactosylation, digalactosylation, sialylation, and IgG3/4 bisection between the two groups. Additionally, the related effector function of antibody-dependent cellular cytotoxicity was found to correlate with these IgG glycoforms, highlighting the importance of glycosylation patterns in modulating immune responses, and guiding personalized vaccination strategies for vulnerable groups.